Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.

Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.

Cancer Sci. 2018 Dec 13;:

Authors: Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, Akamatsu S, Goto T, Watanabe H, Kitaguchi K, Watanabe M, Ono M, Saji H, Ogawa O, Togashi K

Abstract
This first-in-man study was performed to evaluate the safety, whole-body distribution, dose estimation and lesion accumulation of 18 F-FSU-880, a newly-developed probe targeting prostate-specific membrane antigen (PSMA). Six prostate cancer patients with known metastatic lesions underwent serial whole-body positron emission tomography/computed tomography (PET/CT) with 18 F-FSU-880. Blood and urine were analyzed before and after PET/CT. Accumulation of 18 F-FSU-880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole-body effective dose were calculated using OLINDA/EXM software. 18 F-FSU-880 PET/CT could be performed without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10-2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in one patient, whose bone metastases were well-controlled and inactive. PET/CT with 18 F-FSU-880 could be performed safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of 18 F-FSU-880 PET/CT in the management of prostate cancer patients. This article is protected by copyright. All rights reserved.

PMID: 30549183 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2S2wNEB